United Therapeutics Director Tommy G. Thompson Receives RSU Award

What Happened

• Tommy G. Thompson, a director of United Therapeutics Corporation (UTHR), received two awards of restricted stock units (RSUs) reported on Form 4 for July 22, 2026. The grants total 1,570 RSUs (380 RSUs and 1,190 RSUs). The Form 4 reports $0 cash paid — these are derivative awards, not open-market purchases or sales.

Key Details

• Transaction date(s): July 22, 2026. Filing date / Period of Report: filed July 23, 2026 for period 2026-07-22 (appears timely; Form 4 filed within 1 business day).
• Reported price: $0.00 per RSU (awarded). Total reported cash value on the form: $0 (typical for RSU grants reported as derivative acquisitions).
• Shares owned after transaction: not disclosed in this Form 4 (the filing shows the awards received but does not state total beneficial ownership after vesting).
• Notable footnotes:
  • F1: Includes 880 shares issued July 8, 2026 from a July 7, 2023 RSU vesting where Thompson elected to defer receipt.
  • F2: Each RSU represents the right to receive one share of common stock upon vesting.
  • F3: These are annual non-employee director awards.
  • F4: Vesting schedule: RSUs become fully vested on the earlier of (a) one year after grant or (b) the next Annual Meeting of Shareholders (anticipated June 25, 2027).
  • F5: RSUs do not have an expiration date.

Context

• These transactions are grants of RSUs (derivative awards) used for director compensation. They are routine corporate compensation events and do not involve an open-market purchase or sale by the insider.
• RSUs convert into shares only upon vesting; until vested, they represent a promise to deliver shares in the future.